Everything below concerns Preclinical study. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
== Plot == In Chile, Michael Green, a retired former employee of assassin organization Damocles, is killed by a specialist hit squad consisting of decoy Sindy, sniper Facundo, and an assault team of Alexei, Karl, and Hilde, all of whom are also Damocles employees. Duncan Vizla, "The Black Kaiser", is a Damocles employee nearing mandatory retirement on his 50th birthday. By making sizable contributions to his company retirement fund, he is owed over $8 million when he retires. Duncan is pressured into accepting one final contract by Vivian, a common associate of Damocles. He travels to Belarus to fulfill the mission, but finds it was a setup to have him killed. Unknown to him, Mr. Blut, owner of Damocles, plans to sell the company and is inflating its value by murdering its retired operatives, receiving their retirement benefits by way of a clause in their contract that lists Damocles as a beneficiary. Duncan, living in a remote Montana town, is haunted by flashbacks of his violent past. He begins to build a friendship with his troubled new neighbor, Camille. One day, after giving an ill-fated talk at a school about foreign countries and combat, he gives Camille a gun as a gift. While trying to teach her how to shoot, she breaks down, seemingly disturbed by the weapon. Meanwhile, Facundo's squad works to locate Duncan's residence. While beating his accountant, Lomas, they receive a list of his current property holdings. They work through the list without any success, killing the residents of each property.
WJ0679 is a small-molecule oxytocin receptor agonist and vasopressin receptor antagonist. It acts specifically as a very weak partial agonist of the oxytocin receptor (Ki = 422 nM; EC50Tooltip half-maximal effective concentration = 406 nM; EmaxTooltip maximal efficacy = 13%) and as an antagonist of the vasopressin V1A receptor (Ki = 105 nM; IC50Tooltip half-maximal inhibitory concentration = 2,203 nM), whereas no data were reported for the vasopressin V2 receptor. Despite its low activational efficacy at the oxytocin receptor, WJ0679 induces prosocial effects, including increased time spent in close physical contact and increased active social investigation, in rodents. The chemical synthesis of WJ0679 has been described. Along with its close analogue CA7, WJ0679 has the smallest chemical structure known for an oxytocin receptor agonist, with WJ0679 having about 60% of the molecular weight of LIT-001 and both WJ0679 and CA7 lacking LIT-001's tail component. Many analogues of WJ0679 and CA7 have been described. WJ0679 was first described in the scientific literature by a group including Michael Kassiou, Michael Bowen, Iain McGregor, and others at the University of Sydney in 2018. This group has founded a startup pharmaceutical company called Kinoxis Therapeutics and is developing small-molecule oxytocin-related drugs like KNX-100 and the KNX-200 series for potential medical use as of the 2020s.
Naturally occurring tellurium on Earth consists of eight isotopes: 120, 122-126, 128, 130. The heaviest two have been found to be radioactive: 128Te and 130Te undergo double beta decay with half-lives of, respectively, 7.7×1024 years (the longest half-life of all nuclides proven to be radioactive) and 7.9×1020 years. Artificial radioisotopes of tellurium are known, with atomic masses that range from 104 to 142, of which the most stable is 121Te with a half-life of 19.31 days. Several nuclear isomers have longer half-lives, the longest being 121mTe with a half-life of 164.7 days. The very long-lived radioisotopes 128Te and 130Te are the two most common isotopes of tellurium. Of elements with at least one stable isotope, only indium and rhenium likewise have a radioisotope in greater abundance than a stable one. It has been claimed that electron capture of 123Te was observed, but more recent measurements of the same team have disproved this. They have determined the half-life of 123Te to be longer than 9.2 × 1016 years (or 2 × 1015 years without any theoretical assumptions). Its observational stability presents one of only two apparent violations of the Mattauch isobar rule, the other involving 180mTa. 124Te is used as the starting material in the production of certain radionuclides by a cyclotron or other particle accelerator, such as iodine-123 and iodine-124. With the exception of beryllium, tellurium is the lightest element observed to have isotopes capable of undergoing alpha decay, with isotopes 104Te to 109Te being seen to undergo this mode of decay.
Receptor tyrosine kinase, as in fibroblast growth factor receptor. Most enzyme-linked receptors are of this type. Receptor protein serine/threonine kinase, as in bone morphogenetic protein Guanylate cyclase, as in atrial natriuretic factor receptor
Sources: en.wikipedia.org
== Functions and requirement == The Food and Nutrition Board (FNB) of the U.S. Institute of Medicine has set Recommended Dietary Allowances (RDAs) for essential amino acids in 2002. For adults 19 years and older, 19 mg of isoleucine/kg body weight is required daily. Beside its biological role as a nutrient, isoleucine also participates in regulation of glucose metabolism. Isoleucine is an essential component of many proteins. As an essential amino acid, isoleucine must be ingested or protein production in the cell will be disrupted. Fetal hemoglobin is one of the many proteins that require isoleucine. Isoleucine is present in the gamma chain of fetal hemoglobin and must be present for the protein to form. Genetic diseases can change the consumption requirements of isoleucine. Amino acids cannot be stored in the body. Buildup of excess amino acids will cause a buildup of toxic molecules so, humans have many pathways to degrade each amino acid when the need for protein synthesis has been met. Mutations in isoleucine-degrading enzymes can lead to dangerous buildup of isoleucine and its toxic derivative. One example is maple syrup urine disease (MSUD), a disorder that leaves people unable to breakdown isoleucine, valine, and leucine. People with MSUD manage their disease by a reduced intake of all three of those amino acids alongside drugs that help excrete built-up toxins. Many animals and plants are dietary sources of isoleucine as a component of proteins. Foods that have high amounts of isoleucine include eggs, soy protein, seaweed, turkey, chicken, lamb, cheese, and fish.
Ribonucleic acid (RNA) functions in converting genetic information from genes into the amino acid sequences of proteins. The three universal types of RNA include transfer RNA (tRNA), messenger RNA (mRNA), and ribosomal RNA (rRNA). Messenger RNA acts to carry genetic sequence information between DNA and ribosomes, directing protein synthesis and carries instructions from DNA in the nucleus to ribosome . Ribosomal RNA reads the DNA sequence, and catalyzes peptide bond formation. Transfer RNA serves as the carrier molecule for amino acids to be used in protein synthesis, and is responsible for decoding the mRNA. In addition, many other classes of RNA are now known.
On February 26, 1997, Staley and the other members of Alice in Chains attended the Grammy Awards after the song "Again" was nominated for Best Hard Rock Performance. In April of that same year, Staley purchased a 1,500 sq ft (140 m2), three-bedroom condominium in Seattle's University District via the "John LaRusta" trust, an alias used by Staley. Toby Wright, the producer of Alice in Chains' third album, set up a home recording system for him there. In 1998, amid rumors that Staley rarely left his apartment, had contracted gangrene, and had lost the ability to ingest food and was living on a diet of Ensure, Jerry Cantrell told Kerrang! that the members of Alice in Chains regularly hung out at Staley's house. On June 22, 1998, Staley made a phone call to radio program Rockline and gave a rare interview while Cantrell was promoting his first solo album, Boggy Depot. Staley called the show to talk to Cantrell and stated that he had loved the album. In October 1998, Staley re-emerged to record two tracks with Alice in Chains, "Get Born Again" and "Died", which were released on the Music Bank box set in 1999. Additional reports of Staley's deteriorating condition persisted in the midst of the sessions. Dirt producer Dave Jerden—originally chosen by the band for the production—said, "Staley weighed 80 pounds...and was white as a ghost." Studio engineer Elan Trujillo commented that Layne "definitely didn't look like how he used to look" and noticed Staley had, in addition to no teeth, atrophy in his legs.
The word "soviet" is derived from the Russian word sovet (Russian: совет), meaning 'council', 'assembly', 'advice', ultimately deriving from the proto-Slavic verbal stem of *vět-iti ('to inform'), related to Slavic věst ('news') and English wise. The word sovietnik means 'councillor'. Some organizations in Russian history were called council (Russian: совет). In the Russian Empire, the State Council, which functioned from 1810 to 1917, was referred to as a Council of Ministers. The soviets as workers' councils first appeared during the 1905 Russian Revolution. Although they were quickly suppressed by the Imperial army, after the February Revolution of 1917, workers' and soldiers' soviets emerged throughout the country and shared power with the Russian Provisional Government. The Bolsheviks, led by Vladimir Lenin, demanded that all power be transferred to the soviets, and gained support from the workers and soldiers. After the October Revolution, in which they seized power from the Provisional Government in the name of the soviets, Lenin proclaimed the formation of the Russian Socialist Federal Soviet Republic (RSFSR). During the Georgian Affair of 1922, Lenin called for the Russian SFSR and other national soviet republics to form a greater union which he initially named as the Union of Soviet Republics of Europe and Asia (Russian: Союз Советских Республик Европы и Азии, romanized: Soyuz Sovyetskikh Respublik Evropy i Azii).
Despite this, some local populations are listed as endangered, with all the insular subspecies going extinct by the 1800s. Threats to their survival include egg predation by other animals (especially invasive species), roadkills and habitat fragmentation. The emu is an important cultural icon of Australia, appearing on the coat of arms and various coinages. The bird features prominently in Indigenous Australian mythologies.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.